6533b826fe1ef96bd1285350

RESEARCH PRODUCT

The 3-year effect of the mediterranean diet intervention on inflammatory biomarkers related to cardiovascular disease

Rafael LlorachRafael LlorachRamon EstruchRamon EstruchFrancesc CardellachJordi Salas-salvadóMireia Urpi-sardaMireia Urpi-sardaAleix Sala-vilaRosa CasasRosa CasasDolores CorellaDolores CorellaMiguel Ruiz-canelaMiguel Ruiz-canelaEmilio SacanellaCristina Andres-lacuevaCristina Andres-lacuevaGlòria GarrabouMontserrat FitóEmilio Ros

subject

0301 basic medicinemedicine.medical_specialtyMediterranean dietQH301-705.5PopulationMedicine (miscellaneous)Dietary patternInflammationDisease030204 cardiovascular system & hematologyGastroenterologyGeneral Biochemistry Genetics and Molecular BiologyArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicineBiology (General)educationNutricióNutritionInflammationeducation.field_of_studybusiness.industryMalalties cardiovascularsPlasma levelsDietary patternPredimedInflammatory biomarkersExpressió gènicaInflamació030104 developmental biologyCardiovascular diseasesGene expressionmedicine.symptombusiness

description

The intervention with the Mediterranean diet (MD) pattern has evidenced short-term anti-inflammatory effects, but little is known about its long-term anti-inflammatory properties at molecular level. This study aims to investigate the 3-year effect of MD interventions compared to low-fat diet (LFD) on changes on inflammatory biomarkers related to atherosclerosis in a free-living population with a high-risk of cardiovascular disease (CD). Participants (n = 285) in the PREDIMED trial were randomly assigned into three intervention groups: MD with extra-virgin olive oil (EVOO) or MD-Nuts, and a LFD. Fourteen plasma inflammatory biomarkers were determined by Luminex assays. An additional pilot study of gene expression (GE) was determined by RT-PCR in 35 participants. After 3 years, both MDs showed a significant reduction in the plasma levels of IL-1β, IL-6, IL-8, TNF-α, IFN-γ, hs-CRP, MCP-1, MIP-1β, RANTES, and ENA78 (p &lt

10.3390/biomedicines9080862http://hdl.handle.net/10230/53189